{"id":20265,"date":"2021-02-10T00:16:00","date_gmt":"2021-02-10T00:16:00","guid":{"rendered":"https:\/\/celonpharma.com\/?p=20265"},"modified":"2021-02-10T00:16:00","modified_gmt":"2021-02-10T00:16:00","slug":"celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/","title":{"rendered":"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK\/ROCK kinases dual inhibitor, CPL\u2019116.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CPL\u2019116 was administered orally in single ascending doses in healthy volunteers in order to assess&nbsp;safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CPL\u2019116 is the first in class dual JAK\/ROCK inhibitor&nbsp;in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Celon plans to initiate a multiple ascending dose Phase 1b study with safety, pharmacokinetic and pharmacodynamic evaluations in the next coming weeks and expects readouts from this study to be available at the end of 2Q 2021.<\/p>\n\n\n\n<div class=\"wp-block-file\"><a href=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2021\/02\/10022021_JAKROCK-1.docx\">Press information &#8211; Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor<\/a><a href=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2021\/02\/10022021_JAKROCK-1.docx\" class=\"wp-block-file__button\" download>Pobierz<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK\/ROCK kinases dual inhibitor, CPL\u2019116. CPL\u2019116 was administered orally in single ascending doses in healthy volunteers in order to assess&nbsp;safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/\" title=\"ReadCelon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor.\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[28],"tags":[],"class_list":["post-20265","post","type-post","status-publish","format-standard","hentry","category-press-materials"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor. - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor. - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK\/ROCK kinases dual inhibitor, CPL\u2019116. CPL\u2019116 was administered orally in single ascending doses in healthy volunteers in order to assess&nbsp;safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial metRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-10T00:16:00+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/\",\"url\":\"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/\",\"name\":\"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor. - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"datePublished\":\"2021-02-10T00:16:00+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor. - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/","og_locale":"en_US","og_type":"article","og_title":"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor. - CelonGROUP","og_description":"Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK\/ROCK kinases dual inhibitor, CPL\u2019116. CPL\u2019116 was administered orally in single ascending doses in healthy volunteers in order to assess&nbsp;safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial metRead more &raquo;","og_url":"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/","og_site_name":"CelonGROUP","article_published_time":"2021-02-10T00:16:00+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/","url":"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/","name":"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor. - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"datePublished":"2021-02-10T00:16:00+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/celon.group\/en\/2021\/02\/10\/celon-pharma-announces-successful-completion-of-phase-1a-trial-of-cpl116-jak-rock-inhibitor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL\u2019116, JAK-ROCK Inhibitor."}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/20265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=20265"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/20265\/revisions"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=20265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=20265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=20265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}